… Veliparib/placebo could be continued if either carboplatin or … to veliparib/placebo, carboplatin,
and paclitaxel was comparable whether patients were randomized to veliparib or placebo. …

… In this multicenter, double-blind trial, adults with unresectable stage III or IV metastatic
melanoma were randomized 1:1:1 to TMZ plus veliparib 20 or 40 mg, or placebo twice daily. …

… noted with combined veliparib and radiation in … a phase I dose-finding trial followed by a
randomized phase II study to evaluate the safety, tolerability, and preliminary efficacy of veliparib …

… with either placebo, veliparib 200 mg, or veliparib 400 mg. The … QTcF between the veliparib
400 mg dose and placebo (∆∆… ∆∆QTcF between veliparib 400 mg and placebo was below the …

… Veliparib or veliparib placebo administration continued … veliparib placebo, and (C) between
paclitaxel plus carboplatin plus veliparib placebo and paclitaxel plus carboplatin placebo …

… S1416 compared the efficacy of cisplatin plus PARPi veliparib (Vel) or placebo (P) in 3 groups
of MBC: gBRCA+; BRCA-like; and non-BRCA-like. Methods: Patients (pts) with metastatic …

… days) combined with either placebo or veliparib (Days 1-7 q28 days). Veliparib/placebo+TMZ
treatment was continued for up to 6 cycles. Pts accrued on the phase II and III portions of …

… randomized to veliparib plus carboplatin/paclitaxel and 58/172 patients randomized to placebo
… progression and continued on blinded veliparib or placebo monotherapy. In this blinded …

… In summary, BrighTNess was a phase III, randomized, double-blind, placebo-controlled trial
conducted across 145 sites in 15 countries. Eligible patients were women aged ≥18 years …

… , a randomised, controlled, phase 3 trial comparing veliparib with placebo in combination
with … with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. …